Cognition Therapeutics, Inc. (CGTX)
| Market Cap | 89.06M -25.2% |
| Revenue (ttm) | n/a |
| Net Income | -16.78M |
| EPS | -0.19 |
| Shares Out | 95.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 540,018 |
| Open | 0.9800 |
| Previous Close | 0.9508 |
| Day's Range | 0.9335 - 0.9800 |
| 52-Week Range | 0.5501 - 2.0500 |
| Beta | 1.79 |
| Analysts | Strong Buy |
| Price Target | 3.33 (+255.58%) |
| Est. Earnings | Nov 5, 2026 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer’s disease and Mild Cognitive Impairment, as well as geographic atr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CGTX stock is "Strong Buy." The 12-month stock price target is $3.33, which is an increase of 255.58% from the latest price.
News
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Com...
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
As of June 30, 2026, the company reported having approximately $34.8M in cash, cash equivalents, and restricted cash equivalents, alongside $21.6M in total obligated grant funds remaining from the Nat...
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Compa...
Cognition Therapeutics Earnings release: Q2 2026
Cognition Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Cognition Therapeutics Quarterly report: Q2 2026
Cognition Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Cognition Therapeutics Slides: Investor presentation
Cognition Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Comp...
Cognition Therapeutics gets FDA feedback on zervimesine study
Cognition Therapeutics (CGTX) announced that it received written feedback from the FDA following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies could be an...
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
Cognition Therapeutics Transcript: AGM 2026
The meeting was held virtually, confirming quorum and addressing two proposals: election of directors and ratification of the auditor. Both proposals passed by the required vote, with final results to be filed in an 8-K. A Q&A session followed the formal meeting.
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
Cognition Therapeutics (CGTX) announced that a notice of allowance has been received from the United States Patent and Trademark Office, or USPTO, for patent application 19/563,468. The allowed patent...
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative di...
Cognition Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The presentation highlighted a promising oral therapy for psychosis in Lewy body dementia, showing strong efficacy and safety in phase II trials, with a registrational program underway. Alzheimer's data also showed significant slowing of disease progression, and further results are expected next year.
Cognition Therapeutics Slides: Investor presentation
Cognition Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Cognition Therapeutics Participating in Upcoming Investor Conferences
PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Comp...
Cognition Therapeutics conducts zervimesine meeting with FDA
Cognition Therapeutics (CGTX) conducted a planned meeting with the FDA on May 20. The objective of this meeting was to review results from the Phase 2 study of zervimesine and…
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-...
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative dis...
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
“We filed a request to meet with the Food and Drug Administration’s Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body…
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Thera...
Cognition Therapeutics Earnings release: Q1 2026
Cognition Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Cognition Therapeutics Quarterly report: Q1 2026
Cognition Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Cognition Therapeutics Proxy statement: Proxy filing
Cognition Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Cognition Therapeutics Proxy statement: Proxy filing
Cognition Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Preparations are underway for Phase III trials of zervimesine, focusing on DLB psychosis after strong Phase II results and regulatory feedback. The Alzheimer's START trial is fully enrolled, with results expected in Q3 2027, and both programs maintain a favorable safety profile.